We at Novus Biologicals have a large HIF-1 (Hypoxia Inducible Factor-1) antibody catalog, with twenty HIF-1 beta antibody products specifically targeted to the beta subunit of HIF-1, a heterodimer which is known to contribute to many human diseases arising from changes in oxygen homeostasis.
HIF-1 is a transcription factor and key mediator of homeostasis triggered by hypoxia. It drives the transcription of more than 60 genes concerned with anaerobic metabolism, cell survival, cytokine production, the immune reaction, vascularisation and all areas of tissue homeostasis. It is also a key hypoxic regulator of embryonic vascular development.
-Immunohistochemistry-NB100-124-img0004.jpg "Immunohistochemistry: HIF-1 beta Antibody")
HIF-1 alpha and HIF-1 beta antibody studies have shown that the subunits of HIF-1 are dissociated in normoxia. The beta subunit resides in the nucleus while the alpha subunit is cytoplasmic and rapidly ubiquitinized. In conditions of hypoxia, HIF-1 alpha ubiquitinization ceases, allowing it to accumulate in the cytoplasm and relocate to the nucleus, leading to formation of the active HIF-1 heterodimer with HIF-1 beta. This initiates transcription of VEGF, and stabilisation of mRNA.
HIF-1 alpha and HIF-1 beta antibody products are widely used in the study of human disease. Prolonged hypoxia can lead to sepsis, circulatory collapse and rapid organ failure, and is a major contributor to many human diseases, including cerebral and myocardial ischemia, chronic obstructive pulmonary disease, pulmonary hypertension, congenital heart disease and cancer.
The HIF-1 beta antibody products in our antibody catalog are widely used in cancer research, as HIF-1 heterodimer activation is commonly seen in tumor formation, and is associated with angiogenesis via VEGF expression. Recent HIF-1 beta antibody studies by Zhang and others have suggested inhibition of HIF-1 as a possible route for cancer therapy.
Novus Biologicals offers many HIF-1 beta reagents for your research needs including:
